Biotech News
Related news
OCSOculis2026-04-20 08:00 EST
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
OCSOculis2026-06-08 19:25 EST
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
BLTEBelite Bio2026-07-15 12:00 EST
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYOOKYO Pharma2026-07-21 13:00 EST
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYOOKYO Pharma2026-07-27 11:00 EST
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
TARSTarsus Pharmaceuticals2026-05-28 20:30 EST
Tarsus to Participate in Upcoming Investor Conferences
BLTEBelite Bio2026-06-02 12:00 EST
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
IRIXIRIDEX2026-06-09 20:05 EST
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
SGHTSight Sciences2026-03-30 20:05 EST
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
PRQRProQR Therapeutics2026-05-11 12:00 EST
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-08-06 20:05 EST
Oculis Reports Q2 2026 Financial Results and Provides Company Update
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OCSOculis2026-07-08 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Stock data
- Close
- 12.38 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States